Destiny Pharma PLC | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
Destiny Pharma PLC

BRIEF

published on 08/20/2024 at 12:57, 3 months ago

Destiny Pharma to Present XF-73 Nasal Gel Data at ESCMID Conference

Clinical Data Antibiotic Resistance XF-73 Nasal Gel ESCMID Conference Cardiac Surgery
BRIEF

published on 08/20/2024 at 12:57, 3 months ago

Destiny Pharma présentera les données du gel nasal XF-73 à la conférence ESCMID

Résistance Aux Antibiotiques Gel Nasal XF-73 Données Cliniques Conférence De L'ESCMID Chirurgie Cardiaque
PRESS RELEASE

published on 08/20/2024 at 12:52, 3 months ago

Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Destiny Pharma to deliver presentation on XF-73 Nasal Gel at ESCMID conference highlighting rapid reduction in S. aureus nasal burden and lower need for post-operative antibiotics

Destiny Pharma XF-73 Nasal Gel ESCMID Conference S. Aureus Post-operative Antibiotics
BRIEF

published on 08/14/2024 at 12:25, 3 months 6 days ago

Destiny Pharma Initiates Research to Explore XF Drug Potential for CF

Biotechnology Cystic Fibrosis MRSA Drug Research XF-73
BRIEF

published on 08/14/2024 at 12:25, 3 months 6 days ago

Destiny Pharma lance des recherches pour explorer le potentiel du médicament XF pour la mucoviscidose

Biotechnologie XF-73 Fibrose Kystique SARM Recherche Sur Les Médicaments
PRESS RELEASE

published on 08/14/2024 at 12:20, 3 months 6 days ago

Destiny Pharma initiates research to explore XF drug potential for CF
Destiny Pharma initiates research to explore XF drug potential for CF. Study focusing on XF-73 to treat MRSA infection in people with cystic fibrosis. Details on the project and potential benefits

Clinical Study Destiny Pharma XF Drug CF Research MRSA Infection
BRIEF

published on 08/13/2024 at 10:41, 3 months 7 days ago

Destiny Pharma plc Shares Now Trading on JP Jenkins

Biotechnology JP Jenkins Share Trading Destiny Pharma Innovative Medicines
BRIEF

published on 08/13/2024 at 10:41, 3 months 7 days ago

Les actions de Destiny Pharma plc sont désormais négociées sur JP Jenkins

Biotechnologie Négociation D'actions Médicaments Innovants Destin Pharma J.P. Jenkins
PRESS RELEASE

published on 08/13/2024 at 10:36, 3 months 7 days ago

Destiny Pharma plc shares now trading on JP Jenkins
Destiny Pharma plc shares now trading on JP Jenkins. Clinical stage biotechnology company focused on preventing & curing infections. Shares admitted to JP Jenkins trading platform

Shares Biotechnology JP Jenkins Trading Platform Destiny Pharma Plc

Accesswire

Published on 11/21/2024 at 09:00, 39 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 4 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 14 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 39 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 39 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 37 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 39 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 39 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 24 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 29 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 31 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE